Edgar Filing: XOMA Corp - Form 8-K

XOMA Corp Form 8-K August 14, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 14, 2018

XOMA CORPORATION

(Exact name of registrant as specified in its charter)

000-14710 (Commission

Delaware (State or other jurisdiction

52-2154066 (IRS Employer

File Number)

of incorporation)

Identification No.)

2200 Powell Street, Suite 310, Emeryville, California

94608

Edgar Filing: XOMA Corp - Form 8-K

(Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code (510) 204-7200

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: XOMA Corp - Form 8-K

Item 7.01. Regulation FD Disclosure.

On August 14, 2018, XOMA Corporation (the Company) will participate in The Wedbush PacGrow Healthcare Conference taking place in New York, NY, USA on August 14-15, 2018. A copy of the Company s presentation materials has been posted to the Company s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company s royalty assets or business are disclosed in the Risk Factors contained in the Company s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2018, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No. Description

99.1 <u>Corporate Presentation</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XOMA CORPORATION

Date: August 14, 2018

/s/ Thomas Burns Thomas Burns Senior Vice President, Finance and Chief Financial Officer